Session Information
2012 Midyear Clinical Meeting
Click here to go to the previous page
Superbugs! Clinical Controversies in the Management of Multiple-Drug Resistant Bacteria
Track:
New Practitioners Sessions (CE)
Program Code: 308-L01
Date: Sunday, December 2, 2012
Time: 1:45 PM to 3:15 PM EST
Location:
South Seas E, Level 3, South Convention Center
PRESENTER(S):
Click the plus sign to see more detailed information about each speaker.
Click the plus sign to see more detailed information about each speaker.
Jason Pogue, PharmD, BCPS-ID, Clinical Pharmacist, Infectious Diseases, Sinai-Grace Hospital, Detroit Medical Center Molly Steed, PharmD, Clinical Assistant Professor, Infectious Diseases, The University of Kansas School of Pharmacy
PROGRAM CHAIR:
Click the plus sign to see more detailed information about each speaker.
Click the plus sign to see more detailed information about each speaker.
Description
Colistin Dosing: Beans versus Bugs! Rachel Chambers, PharmD
Are Carbapenems Always the Drug of Choice for Extended Spectrum Beta-Lactamase (EBSL) Producers? Jason M. Pogue, PharmD, BCPS-ID
MRSA Bacteremia with Elevated Vancomycin MIC's: Is Daptomycin Really Superior? Molly E. Steed, PharmD
Are Carbapenems Always the Drug of Choice for Extended Spectrum Beta-Lactamase (EBSL) Producers? Jason M. Pogue, PharmD, BCPS-ID
MRSA Bacteremia with Elevated Vancomycin MIC's: Is Daptomycin Really Superior? Molly E. Steed, PharmD
- Apply recent literature on colistin safety and dosing to the care of an individual patient.
- Given an individual patient case, develop a rational, cost effective antimicrobial regimen for the management of methicillin resistant Staphylococcus aureus (MRSA) bacteremia.
- Interpret the literature comparing carbapenems and non-carbapenem beta-lactams for the treatment of ESBL producing enterobacteriaceae.
This session is a part of:
This session is a part of: